Inter- and Intra-Observer Agreement of PD-L1 SP142 Scoring in Breast Carcinoma-A Large Multi-Institutional International Study.

Autor: Zaakouk M; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2TT, UK.; Cancer Pathology, National Cancer Institue, Cairo University, Cairo 12613, Egypt., Van Bockstal M; Department of Pathology, Cliniques Universitaires Saint-Luc Bruxelles, 1200 Brussels, Belgium.; Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, 1348 Brussels, Belgium., Galant C; Department of Pathology, Cliniques Universitaires Saint-Luc Bruxelles, 1200 Brussels, Belgium.; Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, 1348 Brussels, Belgium., Callagy G; Discipline of Pathology, School of Medicine, Lambe Institute for Translational Research, University of Galway, H91 TK33 Galway, Ireland., Provenzano E; NIHR Cambridge Biomedical Research Centre, Cambridge CB2 0QQ, UK.; Addenbrookes Hospital, Cambridge CB2 0QQ, UK.; Department of Histopathology, Cambridge University NHS Foundation Trust, Cambridge CB2 0QQ, UK., Hunt R; Department of Histopathology, Wythenshawe Hospital, Manchester M23 9LT, UK., D'Arrigo C; Poundbury Cancer Institute, Dorchester DT1 3BJ, UK., Badr NM; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2TT, UK.; Department of Pathology, Faculty of Medicine, Menoufia University, Shebin El-Kom 32952, Egypt., O'Sullivan B; Cellular Pathology, Queen Elizabeth Hospital Birmingham, Birmingham B15 2GW, UK., Starczynski J; Cellular Pathology, Heart of England NHS Foundation Trust, Birmingham B9 5ST, UK., Tanchel B; Cellular Pathology, Heart of England NHS Foundation Trust, Birmingham B9 5ST, UK., Mir Y; Pathology, Royal Liverpool and Broadgreen University Hospitals, Liverpool L7 8YE, UK., Lewis P; Medical School, Swansea University, Singleton Park, Swansea SA2 8PP, UK., Shaaban AM; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2TT, UK.; Cellular Pathology, Queen Elizabeth Hospital Birmingham, Birmingham B15 2GW, UK.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2023 Feb 28; Vol. 15 (5). Date of Electronic Publication: 2023 Feb 28.
DOI: 10.3390/cancers15051511
Abstrakt: The assessment of PD-L1 expression in TNBC is a prerequisite for selecting patients for immunotherapy. The accurate assessment of PD-L1 is pivotal, but the data suggest poor reproducibility. A total of 100 core biopsies were stained using the VENTANA Roche SP142 assay, scanned and scored by 12 pathologists. Absolute agreement, consensus scoring, Cohen's Kappa and intraclass correlation coefficient (ICC) were assessed. A second scoring round after a washout period to assess intra-observer agreement was carried out. Absolute agreement occurred in 52% and 60% of cases in the first and second round, respectively. Overall agreement was substantial (Kappa 0.654-0.655) and higher for expert pathologists, particularly on scoring TNBC (6.00 vs. 0.568 in the second round). The intra-observer agreement was substantial to almost perfect (Kappa: 0.667-0.956), regardless of PD-L1 scoring experience. The expert scorers were more concordant in evaluating staining percentage compared with the non-experienced scorers (R 2 = 0.920 vs. 0.890). Discordance predominantly occurred in low-expressing cases around the 1% value. Some technical reasons contributed to the discordance. The study shows reassuringly strong inter- and intra-observer concordance among pathologists in PD-L1 scoring. A proportion of low-expressors remain challenging to assess, and these would benefit from addressing the technical issues, testing a different sample and/or referring for expert opinions.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje